PyroMark Q24 MDx
For IVD-validated mutation and methylation analysis using Pyrosequencing technology
The PyroMark Q24 MDx uses proven Pyrosequencing technology for real-time, sequence-based detection and quantification for in vitro diagnostic use in Europe. This innovative platform is highly suited for genotyping mutations, evaluating disease-related DNA methylation patterns, validating biomarkers, and other diagnostic-related assays.
The PyroMark Q24 MDx is intended for in vitro diagnostic use.